Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors

PURPOSE: The CYP17A1 inhibitor abiraterone markedly reduces androgen precursors and is thereby effective in castration-resistant prostate cancer (CRPC). However, abiraterone increases progesterone, which can activate certain mutant androgen receptors (ARs) identified previously in flutamide-resistan...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Chen, Eddy J., Sowalsky, Adam G., Gao, Shuai, Cai, Changmeng, Voznesensky, Olga, Schaefer, Rachel, Loda, Massimo, True, Lawrence D., Ye, Huihui, Troncoso, Patricia, Lis, Rosina L., Kantoff, Philip W., Montgomery, Robert B., Nelson, Peter S., Bubley, Glenn J., Balk, Steven P., Taplin, Mary-Ellen
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4359958/
https://ncbi.nlm.nih.gov/pubmed/25320358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-1220
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы